| Old | New | Differences | |
|---|---|---|---|
| 1 | 1 | ||
| 2 | 2 | ||
| 3 | 3 | HB 689 2025 | |
| 4 | 4 | ||
| 5 | 5 | ||
| 6 | 6 | ||
| 7 | 7 | CODING: Words stricken are deletions; words underlined are additions. | |
| 8 | 8 | hb689-00 | |
| 9 | 9 | Page 1 of 2 | |
| 10 | 10 | F L O R I D A H O U S E O F R E P R E S E N T A T I V E S | |
| 11 | 11 | ||
| 12 | 12 | ||
| 13 | 13 | ||
| 14 | 14 | A bill to be entitled 1 | |
| 15 | 15 | An act relating to collaborative pharmacy practice for 2 | |
| 16 | 16 | chronic health conditions; amending s. 465.1865, F.S.; 3 | |
| 17 | 17 | excluding specified conditions from the definition of 4 | |
| 18 | 18 | "chronic health condition"; providing an effective 5 | |
| 19 | 19 | date. 6 | |
| 20 | 20 | 7 | |
| 21 | 21 | Be It Enacted by the Legislature of the State of Florida: 8 | |
| 22 | 22 | 9 | |
| 23 | 23 | Section 1. Paragraph (b) of subsection (1) of section 10 | |
| 24 | 24 | 465.1865, Florida Statutes, is amended to read: 11 | |
| 25 | 25 | 465.1865 Collaborative p harmacy practice for chronic 12 | |
| 26 | 26 | health conditions.— 13 | |
| 27 | 27 | (1) For purposes of this section, the term: 14 | |
| 28 | 28 | (b) "Chronic health condition" means: 15 | |
| 29 | 29 | 1. Arthritis; 16 | |
| 30 | 30 | 2. Asthma; 17 | |
| 31 | 31 | 3. Chronic obstructive pulmonary diseases; 18 | |
| 32 | 32 | 4. Type 2 diabetes; 19 | |
| 33 | 33 | 5. Human immunodeficien cy virus or acquired immune 20 | |
| 34 | 34 | deficiency syndrome; 21 | |
| 35 | 35 | 6. Obesity; or 22 | |
| 36 | 36 | 7. Any other chronic condition adopted in rule by the 23 | |
| 37 | 37 | board, in consultation with the Board of Medicine and the Board 24 | |
| 38 | 38 | of Osteopathic Medicine , excluding heart failure, coronary heart 25 | |
| 39 | 39 | ||
| 40 | 40 | HB 689 2025 | |
| 41 | 41 | ||
| 42 | 42 | ||
| 43 | 43 | ||
| 44 | 44 | CODING: Words stricken are deletions; words underlined are additions. | |
| 45 | 45 | hb689-00 | |
| 46 | 46 | Page 2 of 2 | |
| 47 | 47 | F L O R I D A H O U S E O F R E P R E S E N T A T I V E S | |
| 48 | 48 | ||
| 49 | 49 | ||
| 50 | 50 | ||
| 51 | 51 | disease, and cardiac rhythm disorders . 26 | |
| 52 | 52 | Section 2. This act shall take effect July 1, 2025. 27 |